Signs of Multiple Sclerosis Show Up in Blood Years Before Symptoms Appear
UCSF scientists have found a set of autoantibodies that emerge in some MS patients years before symptoms.
University of California San Francisco
Give to UCSFUCSF scientists have found a set of autoantibodies that emerge in some MS patients years before symptoms.
Researchers recently identified a universal, essential biomarker for the childhood cancer neuroblastoma – and the biomarker could be a potential new target for treatment. Neuroblastoma accounts for
UCSF scientists may have discovered a new way to test for autism by measuring how children’s eyes move when they turn their heads.
Rather than simply hearing a string of notes, the brain is assessing them for patterns and predicting which notes will be next.
People with depression have higher body temperatures, suggesting there could be a mental health benefit to lowering the temperatures of those with depression.
Young Black and Hispanic women with multiple sclerosis fare worse than young white women with the disease. Minority women were more likely to have more advanced disease and faced greater challenges in pregnancy.
Early identification of posterior cortical atrophy (PCA) may have important implications for Alzheimer’s treatment. PCA patients struggle with visual impairments like judging distances, distinguishing between moving and stationary objects and completing tasks like writing and retrieving a dropped item.
Fortified stem cells. Enhanced memory. A longevity hormone. UCSF researchers are finding out whether we can cancel – or at least delay – old age.
Thirty-two UCSF scientists are among the most influential individuals in their respective fields, according to the most recent analysis of research citations by the science and intellectual property company, Clarivate.
A previously unknown signaling cycle stemming from our sense of taste helps suppress our appetites.
A gene expression test can accurately predict the best treatment for meningioma patients by measuring the aggressiveness of their tumors and adjusting treatment accordingly.
UCSF's Adam Boxer, MD, PhD, and Harvard neurologist Reisa Sperling, MD, review the history of clinical trials over the past 30 years in Alzheimer’s research with what was learned and how new biomarkers and clinical trial approaches are being used to find more effective treatments in a more efficient way than in the past.
UCSF experts to discuss amyloid therapies and dementia research at CTAD conference, addressing equity, novel treatments, and innovative studies.
A new study will combine an Alzheimer’s medication that slows disease progression in some patients with two other drugs to see if their effects can be amplified.
A brain implant and digital avatar allow a paralyzed stroke survivor to speak with for first time in 18 years with the help of artificial intelligence.
A new digital headset designed to measure alterations in brain function could change decisions about how quickly an athlete is ready to return to play after a concussion.
An experimental blood test that reflects injury to nerve cells from multiple sclerosis (MS) was found to work for children with MS and other neurological conditions, even when they are symptom-free.